- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 86,550 | 14.06.24 17:35:44 | -1,480 | -1,68% | 86,860 | 87,020 | 88,370 | 88,030 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 952,800 | 14.06.24 08:05:16 | -3,200 | -0,33% | 967,400 | 972,200 | 952,800 | 956,000 |
